Drug Pipeline Report 2H 2025

IPD Analytics has released its Drug Pipeline and Trend Impact Report: 2H 2025, a publication that highlights late-stage pipeline drugs with the potential to significantly affect the competitive landscape and payer drug spend across trending drug classes. For each of the 41 drugs identified as having potentially high impact, the report provides an assessment of clinical efficacy and safety, expected place in therapy, approval outlook, estimated cost, and information regarding the reimbursement and distribution channel.

Content on this site is proprietary to IPD Analytics. By receiving this sample you are agreeing to refrain from any unauthorized use, including uploading or inputting into AI tools or large language models for any purpose, is strictly prohibited.